Karuppiah Kannan

Title: The Innovative Contributions of Karuppiah Kannan

Introduction

Karuppiah Kannan is a notable inventor based in Cambridge, MA (US). He has made significant contributions to the field of biomedical research, particularly in the development of methods for producing tumorigenic mouse cells. His work has implications for cancer research and therapeutic testing.

Latest Patents

Kannan holds a patent for a method titled "Directed complementation." This innovative approach involves producing a tumorigenic mouse cell whose tumorigenicity relies on a recombinant gene of interest. The method includes providing a conditionally tumorigenic mouse cell with a recombinant oncogene linked to an inducible promoter. The expression of this oncogene is essential for the tumorigenicity of the cell. Additionally, the method allows for the introduction of a recombinant gene that complements the oncogene, restoring tumorigenicity without the need for oncogene expression. This patent also outlines a method for testing compounds for anti-tumor effects, which includes producing tumorigenic mouse cells, implanting them in mice, and administering test compounds to evaluate their effects.

Career Highlights

Karuppiah Kannan is currently associated with Aveo Pharmaceuticals, Inc., where he continues to advance his research in oncology. His work at the company focuses on innovative solutions for cancer treatment and drug development.

Collaborations

Kannan has collaborated with notable colleagues such as Murray Robinson and Ronan O'Hagan. These partnerships have contributed to the advancement of research in the field of cancer therapeutics.

Conclusion

Karuppiah Kannan's innovative work in developing methods for tumorigenic mouse cells showcases his significant contributions to cancer research. His patent and ongoing work at Aveo Pharmaceuticals, Inc. highlight the importance of innovation in the fight against cancer.